This novel dual WEE1/PKMYT1 inhibitor has the potential to ... a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor ...

GSK acquired Sierra Oncology largely due to the promise of myelofibrosis drug momelotinib, but that biotech’s pipeline also includes CHK1 inhibitor SRA737. Phase 2 work on adavosertib, a WEE1 ...

ACR-2316 is a selective WEE1/PKMYT1 inhibitor ... known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial, focusing ...

The WEE1/PKMYT1 inhibitor is currently in a phase ... Lilly had later picked up the CHK1/2 inhibitor before discarding it in 2019 after phase 2 studies didn't show enough promise.

ACR-2316, a novel, selective dual WEE1 and PKMYT1 inhibitor development ... mechanism of resistance to ACR-368, a clinical-stage CHK1/2 inhibitor, as well as a rational combination treatment ...

This clinical collaboration aims to explore the synergy between Debio 0123, a potential best-in-class, brain-penetrant, and highly selective WEE1 inhibitor, and lunresertib, a first-in-class ...

Poster presentations include dose optimization data for novel Wee1/Myt1 co-inhibitor SGR-3515 and the first characterization of SGR-4174, a novel SOS1 inhibitor Additionally, Schrödinger ...

“Combining with Debiopharm’s highly selective WEE1 inhibitor is the ideal strategy to further extend our leadership in PKMYT1 inhibitor development,” said Lloyd M. Segal, CEO of Repare.